Page last updated: 2024-12-07
2,2-dimethylthiazolidine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
2,2-dimethylthiazolidine: RN given refers to parent cpd; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 88015 |
| SCHEMBL ID | 248542 |
| MeSH ID | M0102627 |
Synonyms (22)
| Synonym |
|---|
| 2,2-dimethylthiazolidine |
| thiazolidine, 2,2-dimethyl- |
| einecs 242-980-4 |
| brn 0102789 |
| 2,2-dimethyl-1,3-thiazolidine |
| 19351-18-9 |
| D1491 |
| A813647 |
| AKOS006230408 |
| 2,2-dimethyltetrahydrothiazole |
| FT-0637834 |
| 2,2-dimethyl thiazolidine |
| dimethylthiazolidine |
| SCHEMBL248542 |
| DTXSID3051832 |
| W-107715 |
| DS-0840 |
| 2,2-dimethyl-1,3-thiazolidine, aldrichcpr |
| CS-W002096 |
| mfcd00014488 |
| AMY2745 |
| EN300-7116656 |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " However, this strategy suffers from the great conformational flexibility small peptides have in solution, which together with bioavailability represents the most important limitation to the usefulness of synthetic peptides as drugs and as synthetic immunogens." | ( Stabilization of the biologically active conformation of the principal neutralizing determinant of HIV-1(IIIB) containing a cis-proline surrogate: 1H NMR and molecular modeling study. Anglister, J; Dumy, P; Garcia, J; Rosen, O, 2006) | 0.33 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (10)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (60.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.74
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.74) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||